Marketed Product. Seller has initiated marketing in the United States of the rare pediatric disease product for which the Priority Review Voucher was awarded within the 365-day period beginning on the date of the FDA approval of such rare pediatric disease product and has marketed such product in the United States since such initiation.
Appears in 2 contracts
Samples: PRV Transfer Agreement (Gw Pharmaceuticals PLC), PRV Transfer Agreement (Biohaven Pharmaceutical Holding Co Ltd.)
Marketed Product. Seller has initiated marketing in the United States of the rare pediatric disease product for which the Priority Review Voucher was awarded within the 365-day period beginning on the date of the FDA approval of such rare pediatric disease product. The rare pediatric disease product and has marketed such product in application for which the United States since such initiationPriority Review Voucher was awarded was not submitted by Seller to the FDA prior to October 7, 2012.
Appears in 1 contract
Samples: Asset Purchase Agreement (Sarepta Therapeutics, Inc.)
Marketed Product. Seller has initiated marketing or will initiate, and subsequently continue, Marketing in the United States of the rare pediatric disease Rare Pediatric Disease product for which the Priority Review Voucher was awarded within the three hundred and sixty five (365-) day period beginning on the date of the FDA approval of such rare pediatric disease product and has marketed such product in the United States since such initiationRare Pediatric Disease product.
Appears in 1 contract
Samples: Asset Purchase Agreement (Eiger BioPharmaceuticals, Inc.)
Marketed Product. Seller has initiated marketing in the United States of the rare pediatric disease product for which the Priority Review Voucher was awarded within the 365-day period beginning on the date of the FDA approval of such rare pediatric disease product and has continuously marketed such product in the United States since such initiationits approval. The rare pediatric disease product application for which the Priority Review Voucher was awarded was not submitted by Seller or Asklepion to the FDA prior to the date that is ninety (90) days after the date of enactment of the Prescription Drug User Fee Amendments of 2012.
Appears in 1 contract